20000425-4

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :		(11) International Publication Number: WO 99/54308
C07D 231/54, A61K 31/41, C07D 409/12, 403/12, 401/12, 417/12, 413/12, 413/14	A1	(43) International Publication Date: 28 October 1999 (28.10.99)

(21) International Application Number: PCT/US99/08616

(22) International Filing Date: 20 April 1999 (20.04.99)

(30) Priority Data:
60/082,476 21 April 1998 (21.04.98) US

(71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; 974 Centre Road, WR-1ST18, Wilmington, DE 19807 (US).


(72) Inventors: NUGIEL, David, A.; 8 Vanessa Court, Cherry Hill, NJ 08003 (US). CARINI, David, J.; 1921 Julian Road, Wilmington, DE 19803 (US). YUE, Eddy, W.; 9 Altemus Drive, Landenberg, PA 19350 (US). DIMEO, Susan, V.; 206 Clayton Avenue, Wilmington, DE 19809 (US).

(74) Agent: VANCE, David, H.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS



(I)

(57) Abstract

The present invention relates to the synthesis of a new class of indeno [1,2-c]pyrazol-4-ones of formula (I), that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits known as cyclines A-G. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.